/daily ·27 JUL 2026 ·MONDAY ·3 MIN READ ·5 STORIES

FDA Splits the Peptide Vote, Salk Finds Zombie Cells' Weakness, and GBD Says Healthy Years Aren't Keeping Pace

The FDA advisory panel divides its verdict — epitalon approved, emideltide rejected — as Salk researchers find a specific enzyme that makes senescent cells vulnerable to a targeted form of cell death, and a Lancet analysis confirms the troubling arithmetic: more years lived, fewer of them healthy.

01 / The Day

MONDAY 27 JUL 2026, ranked

FDA panel backs epitalon compounding, narrowly rejects emideltide

An FDA advisory committee voted to recommend authorising compounding pharmacies to produce epitalon, a peptide studied for telomere and immune effects, while narrowly rejecting emideltide in a separate vote. The split outcome is part of an ongoing series of FDA panels evaluating whether peptide compounds qualify as bulk drug substances eligible for pharmacy compounding.

Why it mattersApproval compound-by-compound rather than class-by-class creates an inconsistent regulatory landscape — and leaves physicians uncertain about which peptides are legally compoundable from which type of pharmacy.

01 statnews.com↗

Salk Institute: acid ceramidase makes zombie cells vulnerable to ferroptosis

Researchers at the Salk Institute found that the enzyme acid ceramidase is elevated in senescent cells and that this elevation makes them unusually vulnerable to ferroptosis, an iron-mediated form of cell death. Inhibiting acid ceramidase selectively eliminated senescent human lung cells in laboratory experiments while leaving neighbouring healthy cells largely intact. Drugs targeting acid ceramidase are already in development for cancer. The study was published in Cell Death and Disease.

Why it mattersA mechanism specific to senescent cells — not a general pro-apoptotic signal — is precisely what a senolytics programme needs to avoid harming healthy tissue alongside its targets.

02 doi.org↗

GPR40 agonism restores thymic T-cell production in aged mice

A small-molecule agonist of GPR40, a fatty acid receptor expressed in thymic tissue, substantially restored T-cell production in aged mice, reversing the thymic involution that reduces immune competence with age. The compound was orally bioavailable and showed no significant off-target effects at effective doses in the mouse model.

Why it mattersThymic regeneration is one of the more tractable targets in aging biology — the organ's decline is well-characterised, directly measurable, and causally linked to reduced immunity — making GPR40 a specific therapeutic candidate with a clear endpoint.

03 fightaging.org↗

Metabolic syndrome associated with measurably older-appearing brains in large UK Biobank study

A UK Biobank imaging study found that middle-aged adults with metabolic syndrome had brains that appeared significantly older on MRI — quantified as a higher brain age gap — than matched individuals without the condition. Eight circulating metabolites including inflammatory markers and lipid metabolism intermediates partially mediated the association. The study was published in Alzheimer's and Dementia.

Why it mattersA modifiable cluster of conditions — hyperglycaemia, hypertension, central obesity, dyslipidaemia — is measurably associated with accelerated brain ageing; the metabolite mediators identified point toward specific intervention targets rather than general lifestyle advice.

04 doi.org↗

Global Burden of Disease 2023: lifespan gains have not been matched by healthspan gains

A systematic analysis for the Global Burden of Disease Study 2023, published in The Lancet Public Health, found that while global life expectancy rose substantially between 1990 and 2023, years spent in poor health expanded in nearly every country. The morbidity gap — the difference between total lifespan and healthy lifespan — now exceeds a decade for most national populations.

Why it mattersThe analysis reframes the success metric for medicine and public health: extending life while expanding the sick period is not an unambiguous win — and quantifying the gap is the first step toward treating it as a design target.

05 thelancet.com↗

Be subscriber #012 the weekly ten, every friday by email · no spam · unsubscribe anytime

Past days

The Daily Archive

/FRI 31 JULBlood proteins predict liver disease 16 years early /WED 29 JULWednesday, 29 July — Clocks, guts, heat /MON 27 JULFDA Splits the Peptide Vote, Salk Finds Zombie Cells' Weakness, and GBD Says Healthy Years Aren't Keeping Pace /FRI 24 JULThe Drug That Lost Its Heart /WED 22 JULBlood, bone, and the morbidity gap /FRI 17 JULFriday in Longevity: Clocks, Fat, and Immune Decay /WED 15 JULSenescent terrain /MON 13 JULLecanemab under the skin /FRI 10 JULLongevity | Jul 10 2026: Gut, Senescence, Epigenetics /WED 08 JULDrugs remapped to aging hallmarks, ovarian aging reversed, and a 50% molecular gap /MON 06 JULCentenarian chemistry, sleeping circuits, and reprogrammed eyes /FRI 03 JULOvaries, progenitors, and oxygen /WED 01 JULTelomere signals, proteomic clocks, and faster biological aging /MON 29 JUNMonday, June 29 — Longevity /FRI 26 JUNWhen you sleep matters; what your cells do with miscopied RNA also matters /TUE 23 JUNGenes, Clocks, and GLP-1s /MON 22 JUNMonday: Senescent cells, climbing clocks, and late-life gene therapy /FRI 19 JUNLongevity — June 19, 2026 /WED 17 JUNClocks, Loops, and One Very Productive Bacteria /MON 15 JUNReprogramming closes first human trial; circadian link firms /FRI 12 JUNAging regimes, borrowed sleep, and a race to measure biological age